argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023

Argenx does not have a long track record of dividend growth. There may be delays, omissions, or inaccuracies in the Information. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%.

Provide specific products and services to you, such as portfolio management or data aggregation. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Argenx is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

A webcast of the live call may be customer relationship managemented on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.

argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Style is an investment factor that has a meaningful impact on investment risk and returns.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 .

• The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
• Upgrade to MarketBeat All Access to add more stocks to your watchlist.
• More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
• The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.

High institutional ownership can be a signal of strong market trust in this company. In the past three months, argenx insiders have not sold or bought any company stock. MarketBeat has tracked 9 news articles for argenx this week, compared to 3 articles on an average week. Argenx has a short interest ratio (“days to cover”) of 4.2. 1.70% of the outstanding shares of argenx have been sold short. With a price/sales ratio of 2,014.54, ARGENX SE has a higher such ratio than 99.71% of stocks in our set.

argenx SE ADR

Only 1 people have added argenx to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Intraday Data provided by FACTSET and subject to terms of use.

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indi… Raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat’s FREE daily newsletter.

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of ARGX stock can currently be purchased for approximately $387.88. Biden’s disturbing new government program may be worse than Obama’s. A former bank regulator is blowing the whistle on Biden’s frightening plan to take over your money.

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023.

argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod

We have 9 different ratings for every stock to help you appreciate its future potential. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. We’d like to share more about how we work and what drives our day-to-day business. CompareARGX’s historical performanceagainst its industry peers and the overall market.

• Argenex SE might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 .
• The group has partnered with academic researchers through its Immunology Innovation Program and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines.
• The company issued 3,600,000 shares at a price of $18.18 per share.
• The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

Stocks with similar financial metrics, market capitalization, and price volatility to ARGENX SE are TGTX, GLYC, GERN, RETA, and LXRX. The technique has proven to be very useful for finding positive surprises. Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings. Real-time analyst ratings, insider transactions, earnings data, and more. The P/E ratio of argenx is -29.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Related News ARGX

An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. Argenex SE might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 . © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Below are the latest news stories about ARGENX SE that investors may wish to consider to help them evaluate ARGX as an investment opportunity. As for revenue growth, note that ARGX’s revenue has grown -75.11% over the past 12 months; that beats the revenue growth of only 2.32% of US companies in our set. ARGX scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.96% of US stocks.

https://1investing.in/ developed and is commercializing the neonatal Fc receptor blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others. 18 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for argenx in the last year. There are currently 1 hold rating and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” ARGX shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Argen X SE – ADR 52 week low is $267.35 as of April 29, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year.

Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.

The Motley Fool Paid Partner

Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Argen X SE – ADR 52 week high is $407.93 as of April 29, 2023. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. De Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines.